Arcutis (ARQT) Q4 2023: Zoryve Foam Launch Drives 67% Sequential Revenue Growth, Expanding Addressable Market

February 27, 2024 | By EarningsIQ Research

Arcutis’s Q4 marked a turning point as Zoryve Foam’s rapid uptake in seborrheic dermatitis propelled sequential revenue growth, while the company positioned itself for major market expansion in 2024. Early evidence suggests pent-up demand and unmet need are translating to strong initial adoption, with payer access and commercial execution supporting further acceleration. Investors should watch for Medicare and Medicaid access, atopic dermatitis approval, and operating leverage as the next phases unfold.

Summary

• Foam Launch Outpaces Expectations: Zoryve Foam’s debut in seborrheic dermatitis set a new launch benchmark for Arcutis.
• Commercial Model Scaling Rapidly: Prescription growth and coverage gains are driving momentum across both cream and foam franchises.
• Medicare, Medicaid, and AD Indication: Near-term access and label expansion will be critical levers for sustained revenue acceleration in 2024.

Business Overview

Arcutis Biotherapeutics develops and commercializes topical therapies for chronic dermatologic conditions. The company’s revenue is driven by sales of Zoryve, a topical PDE4 inhibitor, offered as a cream for plaque psoriasis and, newly, as a foam for seborrheic dermatitis. Arcutis’s core business segments include prescription pharmaceutical sales, with further growth targeted via upcoming indications such as atopic dermatitis and expanded payer access.

Performance Analysis

Arcutis delivered a breakout quarter, with Zoryve Foam’s launch in seborrheic dermatitis catalyzing a 67% sequential increase in net product revenue. The company’s prescription base is expanding rapidly, with over 165,000 total prescriptions and more than 10,700 unique prescribers since launch. Q4 saw a 26% quarter-over-quarter rise in Zoryve prescriptions and a 39% jump in refills, now comprising over one-third of total scripts—an indicator of growing patient retention and satisfaction.

Gross to net improvements, a key pharmaceutical metric reflecting realized revenue after discounts and rebates, advanced to the mid-60% range in Q4, building on consecutive quarterly progress. Management underscored the importance of payer coverage, with Zoryve Cream now accessible to over 132 million commercial lives and all three major U.S. pharmacy benefit managers (PBMs) onboarded within 12 months of launch. Notably, Zoryve Foam prescriptions are already nearing 50% coverage early in launch, suggesting a faster gross to net ramp than the cream.

• Foam Launch Traction: Zoryve Foam’s initial prescription velocity outpaced both Zoryve Cream and historical competitors, reflecting pent-up demand and lack of innovation in the indication.
• Refill and Retention Dynamics: Refill rates reached 38% of total volume, supporting durable demand and patient satisfaction.
• Operating Leverage in Focus: R&D expenses declined meaningfully as late-stage studies wound down, while SG&A increased to support multiple launches, with management targeting $50 million in operating expense reductions over two years.

Arcutis’s financial position was strengthened by a $102 million secondary offering, ending the year with $273 million in cash and marketable securities. The company also recorded $30 million in collaboration revenue, further supporting its balance sheet.

Executive Commentary

Strategic Positioning

1. Zoryve Foam Launch as a Market Catalyst

Zoryve Foam’s approval and launch for seborrheic dermatitis—an indication with no new branded options in over two decades—has unlocked a new patient pool and established Arcutis as a first-mover. Early prescriber enthusiasm and high initial coverage rates are accelerating adoption, with management highlighting the product’s convenience, efficacy, and rapid itch relief as differentiators.

2. Payer Access and Gross to Net Optimization

Arcutis’s commercial strategy centers on rapid payer coverage expansion and gross to net improvement, leveraging differentiated pricing and broad PBM access. The company aims to approach a gross to net in the 50% range for psoriasis by year-end, with foam and future indications expected to benefit from similar coverage dynamics. Medicare and Medicaid penetration, representing a third to half of the patient base in key indications, is a substantial upcoming tailwind.

3. Pipeline and Label Expansion

The supplemental NDA for Zoryve Cream in atopic dermatitis (AD) down to age six, with a July 2024 FDA action date, positions Arcutis to address a large, underserved market. Long-term data show durable efficacy and safety, with management confident in rapid adoption, particularly among pediatric patients where non-steroidal demand is high. Additional sNDA filings for foam in scalp and body psoriasis are planned for the second half of 2024.

4. Commercial Execution and Field Force Scaling

The commercial team is expanding by 50% ahead of the anticipated AD launch, reflecting management’s commitment to full-market coverage and prescriber education. The Zoryve Direct fulfillment program, unified across cream and foam, simplifies office workflows and supports efficient uptake.

5. Financial Stewardship and Capital Allocation

Arcutis has reprioritized non-commercial spending and reduced operating expenses by $50 million over two years, aligning resources with commercial execution and launch readiness. The company is also exploring primary care partnerships and out-licensing in Japan to generate non-dilutive capital and extend runway.

Key Considerations

This quarter’s results underscore Arcutis’s transition from a development-stage to a commercial-stage company, with operational discipline and strategic focus on high-value launches. The expansion into new indications and payor segments will test the scalability of both the commercial infrastructure and the Zoryve franchise.

Key Considerations:

• Medicare and Medicaid Access Timing: Coverage is expected to ramp piecemeal through 2024, with material impact likely in the second half as state and Part D negotiations conclude.
• Atopic Dermatitis Approval as a Growth Inflection: A positive FDA decision in July could unlock a much larger addressable market, especially among pediatric patients and non-steroidal seekers.
• Gross to Net Volatility: Expect temporary Q1 pressure from deductible resets and coverage transitions, but management is targeting improvement through 2024.
• Foam and Cream Synergy: Unified fulfillment and coverage strategies should drive operational leverage and cross-indication prescriber adoption.

Risks

Arcutis faces execution risk as it scales its commercial footprint and launches into new indications with different payer and competitive dynamics. Delays in Medicare or Medicaid access, slower-than-expected AD uptake, or unforeseen gross to net headwinds could dampen revenue trajectory. Additionally, the company’s multi-launch strategy increases near-term SG&A demands, with operating leverage dependent on successful uptake and coverage expansion.

Forward Outlook

For Q1 2024, management cautioned about temporary gross to net erosion in psoriasis due to deductible resets and plan changes but expects continued prescription growth for both cream and foam. For full-year 2024:

• Gross to net for psoriasis targeted in the 50% range by second half.
• R&D expenses expected to decline meaningfully as late-stage studies wind down.
• SG&A to increase, supporting atopic dermatitis launch and field force expansion.

Management highlighted:

• Pending FDA decision for Zoryve Cream in atopic dermatitis (July 2024).
• Medicare and Medicaid coverage ramping through mid-to-late 2024.

Takeaways

• Foam Launch Redefines Growth Curve: Zoryve Foam’s early success in seborrheic dermatitis validates Arcutis’s commercial strategy and addresses a large, underserved market.
• Coverage and Access Remain Central Levers: The speed of payer coverage and gross to net improvement will dictate realized revenue and margin trajectory.
• 2024 Hinges on Execution: Atopic dermatitis approval, Medicare/Medicaid access, and operational scaling are the key catalysts and risks for the year ahead.

Conclusion

Arcutis enters 2024 with accelerating momentum, a broadened commercial footprint, and multiple near-term catalysts. The company’s ability to translate initial launch success into durable, profitable growth will hinge on payer access, operational discipline, and execution in new indications. Investors should monitor adoption curves, coverage progress, and expense scaling as the next phase unfolds.

Industry Read-Through

Arcutis’s rapid payer access and prescription growth for Zoryve Foam signal that pent-up demand and product innovation can drive outsized early adoption in underserved dermatology indications. The company’s unified commercial infrastructure and focus on gross to net management provide a playbook for emerging biotech peers seeking to scale in specialty pharma. The foam’s success also highlights the value of first-mover advantage where branded competition is absent, and underscores the importance of payer strategy and field force agility in driving launch velocity. Competitors in dermatology and adjacent specialty markets should note the commercial and operational blueprint Arcutis is executing as payer dynamics and patient expectations evolve.

ARQT Healthcare Pharmaceuticals Dermatology Product Launch Payer Access Prescription Growth Medicare